Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer’s disease based on the A/T(N) research framework

Wang, Ye; Zhang, Yuhan; Yu, Enyan

doi:10.1016/j.clineuro.2023.108071

Cited by 5 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It affects millions of individuals worldwide, and its prevalence is expected to rise significantly as the global population ages [2]. The pathological hallmarks of Alzheimer's disease include the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, which are believed to contribute to the disease's progression [3].…”

Section: Introductionmentioning

confidence: 99%

Classifying Beta-Secretase 1 Inhibitor Activity for Alzheimer’s Drug Discovery with LightGBM

Noviandy,

Nisa,

Idroes

et al. 2024

J. Comput. Theor. Appl.

View full text Add to dashboard Cite

This study explores the utilization of LightGBM, a gradient-boosting framework, to classify the inhibitory activity of beta-secretase 1 inhibitors, addressing the challenges of Alzheimer's disease drug discovery. The study aims to enhance classification performance by focusing on overcoming the limitations of traditional statistical models and conventional machine-learning techniques in handling complex molecular datasets. By sourcing a dataset of 7298 compounds from the ChEMBL database and calculating molecular descriptors for each compound as features, we employed LightGBM in conjunction with a set of carefully selected molecular descriptors to achieve a nuanced analysis of compound activities. The model's efficiency was benchmarked against traditional machine-learning algorithms, revealing LightGBM's superior accuracy (84.93%), precision (87.14%), sensitivity (89.93%), specificity (77.63%), and F1-score (88.17%) in classifying beta-secretase 1 inhibitor activity. The study underscores the critical role of molecular descriptors in understanding drug efficacy, highlighting LightGBM's potential in streamlining the virtual screening process. Conclusively, the findings advocate for LightGBM's adoption in computational drug discovery, offering a promising avenue for advancing Alzheimer's disease therapeutic development by facilitating the identification of potential drug candidates with enhanced precision and reliability.

show abstract

Section: Introductionmentioning

confidence: 99%

Classifying Beta-Secretase 1 Inhibitor Activity for Alzheimer’s Drug Discovery with LightGBM

Noviandy,

Nisa,

Idroes

et al. 2024

J. Comput. Theor. Appl.

View full text Add to dashboard Cite

show abstract

Precision neurology

Small

2025

Ageing Research Reviews

View full text Add to dashboard Cite

Toxic Advanced Glycation End-Products-Dependent Alzheimer’s Disease- Like Alternation in the Microtubule System

Ooi,

Koriyama

2023

CAR

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's Disease (AD). However, the detailed mechanism underlying T2DM-related AD remains unknown. In DM, many types of advanced glycation end products (AGEs) are formed and accumulated. In our previous study, we demonstrated that Glyceraldehyde (GA)-derived toxic Advanced Glycation End products (toxic AGEs, TAGE) strongly showed cytotoxicity against neurons and induced similar alterations to those observed in AD. Further, GA induced dysfunctional neurite outgrowth via TAGE-β-tubulin aggregation, which resulted in the TAGE-dependent abnormal aggregation of β-tubulin and tau phosphorylation. Herein, we provide a perspective on the possibility that T2DM increases the probability of AD onset and accelerates its progression.

show abstract

Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer’s disease based on the A/T(N) research framework

Cited by 5 publications

References 67 publications

Classifying Beta-Secretase 1 Inhibitor Activity for Alzheimer’s Drug Discovery with LightGBM

Classifying Beta-Secretase 1 Inhibitor Activity for Alzheimer’s Drug Discovery with LightGBM

Precision neurology

Toxic Advanced Glycation End-Products-Dependent Alzheimer’s Disease- Like Alternation in the Microtubule System

Contact Info

Product

Resources

About